**Body System:** Cardiovascular  
**Session Topic:** Cardiovascular Pharmacology  

<table>
<thead>
<tr>
<th>Educational Format</th>
<th>Faculty Expertise Required</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REQUIRED</strong></td>
<td>Interactive Lecture</td>
</tr>
<tr>
<td><strong>OPTIONAL</strong></td>
<td>Problem-Based Learning (PBL)</td>
</tr>
</tbody>
</table>

**Professional Practice Gap**

- Preventable cardiovascular medication errors are common in the US
- Preventable medication errors are higher with regard to look-alike or sound-alike names, omission, dosing, dispensing, and timing
- Communication failures and poor care coordination are major sources of medication errors for patients with acute stroke
- Physicians are frequently non-adherent to cardiovascular practice guidelines
- Patients frequently exhibit poor medication adherence

**Learning Objective(s) that will close the gap and meet the need**

1. Establish protocols for the consistent application of current practice guidelines for the treatment of common cardiovascular conditions.
2. Determine when a patient’s medication history or overall health may produce severe side effects or interfere with treatment for a cardiovascular condition.
3. Develop a collaborative treatment plan for common cardiovascular conditions, emphasizing medication adherence and monitoring.
4. Design a care coordination and communication plan with all members of the cardiovascular care team.

**Outcome Being Measured**

Learners will submit written commitment to change statements on the session evaluation, indicating how they plan to implement presented practice recommendations.

**ACGME Core Competencies Addressed** (select all that apply)

<table>
<thead>
<tr>
<th>Competency</th>
<th>Patient Care</th>
<th>Practice-Based Learning and Improvement</th>
<th>Systems-Based Practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>X Medical Knowledge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X Interpersonal and Communication Skills</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professionalism</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Faculty Instructional Goals**

Faculty play a vital role in assisting the AAFP to achieve its mission by providing high-quality, innovative education for physicians, residents and medical students that will encompass the art, science, evidence and socio-economics of family medicine and to support
the pursuit of lifelong learning. By achieving the instructional goals provided, faculty will facilitate the application of new knowledge and skills gained by learners to practice, so that they may optimize care provided to their patients.

- Provide up to 3 evidence-based recommended practice changes that can be immediately implemented, at the conclusion of the session; including SORT taxonomy & reference citations
- Facilitate learner engagement during the session
- Address related practice barriers to foster optimal patient management
- Provide recommended journal resources and tools, during the session, from the American Family Physician (AFP), Family Practice Management (FPM), and Familydoctor.org patient resources; those listed in the References section below are a good place to start
  - Visit http://www.aafp.org/journals for additional resources
  - Visit http://familydoctor.org for patient education and resources
- Provide recommendations for establishing protocols for the consistent application of current practice guidelines for the treatment of common cardiovascular conditions.
- Provide recommendations for determining when a patient’s medication history or overall health may produce severe side effects or interfere with treatment for a cardiovascular condition.
- Provide strategies and resources for developing a collaborative treatment plan for common cardiovascular conditions, emphasizing medication adherence and monitoring.
- Provide strategies and resources for designing a care coordination and communication plan with all members of the cardiovascular care team.
- Provide recommendations regarding new FDA approved medications for the treatment of a variety of cardiology/vascular diseases; including safety, efficacy, tolerance, and cost considerations relative to currently available options.
- Provide recommendations regarding guidelines for Medicare reimbursement.
- Provide recommendations to maximize office efficiency and guideline adherence to the diagnosis and management of
- Provide instructions regarding the incorporation and use of the PCMH/ACO/Primary Care Core Measure Set into practice.

Needs Assessment
Of the 214 million office visits to general and family practitioners in the United States in 2010, medications for cardiovascular issues were among the top 5 most prescribed during 85% of those office visits. Many recent reports on patient safety suggest that as many as half of patients suffering acute myocardial infarctions fail to receive aspirin and β-blockers, and thromboprophylaxis with oral anticoagulants is often underutilized in treating patients with atrial fibrillation, due to errors of omission that could cost more lives and cause more disability that errors resulting from negligent practice. In addition, of the 450,000 preventable medication-related adverse events that occur each year in the US, cardiovascular medications prescribed to inpatients account a large portion of those errors, averaging one medication error per day. In general, errors are higher with regard to medications with look-alike or sound-alike names, but
medication dosing, dispensing, and timing errors are also common; more specifically common medication errors for:5,6

- Patients with acute coronary syndrome (ACS) – dosing, omission (initial treatment or resuming treatment), and miscalculation of a patient’s weight.
  - Non-optimal dosing of antiplatelet agents
  - Incorrect dosing of fibrinolytic agents
  - Incorrect dosing of anticoagulant agents
- Omission medication errors involving statins
- Patients with acute heart failure are prone to polypharmacy and associated issues with dosing, timing, and drug-drug interactions
- Communication failures and poor care coordination are major sources of medication errors for patients with acute stroke
- Nonadherence to practice guidelines

Data from a recent American Academy of Family Physicians (AAFP) CME Needs Assessment survey indicate that family physicians have knowledge gaps with regard to optimal cardiovascular pharmacological management.7 More specifically, CME outcomes data from 2012-13, and 2015-16 AAFP FMX (formerly Assembly): Cardiovascular Pharmacology sessions suggest that physicians have knowledge and practice gaps with regard to appropriate use of ACE in first line treatment; appropriate and earlier use of beta-blockers; use of a care coordinator for post discharge; more appropriate use of staging criteria; consistent adherence to guidelines; effectively counseling patients to foster medication adherence; and more effective use of atenolol, metoprolol, and spironolactone generally.8-11

Several factors may contribute to suboptimal use of antiplatelet therapies, including lack of awareness or familiarity with guidelines, complex guidelines, complex medical regimens, poor coordination of care with cardiologists, and lack of knowledge and skills to use adherence-improving tools or resources with their staff or patients.6,12-14 A recent review of the literature suggests that nonsteroidal anti-inflammatory drug (NSAID) use is associated with increased risk of bleeding and cardiovascular disease in patients receiving antithrombotic therapy.15,16 Additionally, recent research suggests that testosterone injectables may be associated with an increase in cardiovascular risk.17-19

A recent review of the literature reveals the following cardiovascular pharmacology updates:20-22

- Oral beta blockers should be started within 24 hours of presentation of acute coronary syndrome, if there are no contraindications.
- Treatment with ACE inhibitors is recommended in persons with a left ventricular ejection fraction less than 0.40, hypertension, diabetes mellitus, or stable chronic kidney disease.
- Chewable aspirin without an enteric coating, at a dose of 162 to 325 mg, should be administered as soon as possible to patients presenting with symptoms suggestive of acute coronary syndrome.
- Dual antiplatelet therapy with ticagrelor or clopidogrel in combination with aspirin should be given for up to one year in the invasive and ischemia-guided treatment approaches to ST elevation myocardial infarction and non-ST elevation acute coronary syndrome.
• Patients taking warfarin (Coumadin) should be treated using systematic processes of care to optimize effectiveness and minimize adverse effects. Health care professionals skilled in the initiation and assessment of therapy and dosing adjustments can dramatically influence outcomes.

• In patients with atrial fibrillation and at least one other risk factor for stroke, direct oral anticoagulants (e.g. dabigatran, rivaroxaban, apixaban, and edoxaban) that do not require frequent laboratory monitoring are as effective as warfarin for prevention of stroke or systemic embolism and have comparable risks of major bleeding.

• Compared with usual clinic-based care, patient self-testing for international normalized ratios, with or without self-dosing of warfarin, is associated with significantly fewer deaths and thromboembolic complications without any increase in bleeding complications for a selected group of motivated patients who have completed appropriate training.

The U.S. Food and Drug Administration (FDA) has approved a number of new drugs in recent years for the treatment of a variety of cardiology/vascular diseases. Physicists need to be kept up to date on new treatment options, including safety, efficacy, tolerance, and cost considerations relative to currently available options. Examples from the last five years include, but are not limited to the following:

**Drugs Approved in 2017**
- Bevyxxa (betrixaban); Portola Pharmaceuticals; For the prophylaxis of venous thromboembolism, Approved June 2017

**Drugs Approved in 2016**
- Byvalson (nebivolol and valsartan); Allergan; For the treatment of hypertension, Approved June 2016
- Yosprala (aspirin and omeprazole); Aralez Pharmaceuticals; For the prevention of cardiovascular and cerebrovascular events, Approved September 2016

**Drugs Approved in 2015**
- Corlanor (ivabradine); Amgen; For the treatment of chronic heart failure, Approved April 2015
- Entresto (sacubitril and valsartan); Novartis; For the treatment of chronic heart failure, Approved July 2015
- Kanuma (sebelipase alfa); Alexion; For the treatment of Lysosomal Acid Lipase (LAL) deficiency, Approved December 2015
- Kengreal (cangrelor); The Medicines Company; For reducing periprocedural thrombotic events, Approved June 2015
- Praluent (alirocumab); Sanofi Aventis; For the treatment of heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, Approved July 2015
- Prestalia (perindopril arginine and amlodipine besylate); Symplmed Pharmaceuticals; For the treatment of hypertension, Approved January 2015
- Repatha (evolocumab); Amgen; For the treatment of high cholesterol, Approved August 2015
- Savaysa (edoxaban); Daiichi Sankyo; For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation, Approved January 2015
• **Drugs Approved in 2014**
  - Uptravi (selexipag); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved December 2015
  - Epanova (omega-3-carboxylic acids); AstraZeneca; For the treatment of severe hypertriglyceridemia, Approved May 2014
  - Zontivity (vorapaxar); Merck; For the reduction of thrombotic cardiovascular events, Approved May 2014

• **Drugs Approved in 2013**
  - Adempas (riociguat); Bayer Healthcare Pharmaceuticals; For the treatment of Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension, Approved October 2013
  - Kynamro (mipomersen sodium); Genzyme; For the treatment of homozygous familial hypercholesterolemia, Approved January 2013
  - Liptruzet (ezetimibe and atorvastatin); Merck; For the treatment of hyperlipidemia, Approved May 2013
  - Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013
  - Opsumit (macitentan); Actelion Pharmaceuticals; For the treatment of pulmonary arterial hypertension, Approved October 2013
  - Varithena (polidocanol injectable foam); BTG plc; For the treatment of varicose veins, November 2013

• **Drugs Approved in 2012**
  - Eliquis (apixaban); Bristol-Myers Squibb; For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation, Approved December 2012
  - Juxtapid (lomitapide); Aegerion Pharmaceuticals; For the treatment of homozygous familial hypercholesterolemia, Approved December of 2012
  - Vascepa (icosapent ethyl); Amarin Pharmaceuticals; For the treatment of hypertriglyceridemia, Approved July of 2012

• **Drugs Approved in 2011**
  - Brilinta (ticagrelor); AstraZeneca; For the reduction of thrombotic events in patients with acute coronary syndrome, Approved July 2011
  - Edarbi (azilsartan medoxomil); Takeda; For the treatment of hypertension, Approved February 2011
  - Edarbyclor (azilsartan medoxomil and chlorthalidone); Takeda; For the treatment of hypertension, Approved December of 2011
  - Xarelto (rivaroxaban); Bayer; For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011
  - Xarelto (rivaroxaban); Janssen Pharmaceuticals; For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011

• **Drugs Approved in 2010**
  - Âmturnide (aliskiren + amlodipine + hydrochlorothiazide); Novartis; For the treatment of uncontrolled hypertension, Approved December 2010
  - Pradaxa (dabigatran etexilate mesylate); Boehringer Ingelheim; For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010
In addition to physician and systems related factors of cardiovascular medication errors, nearly half of the 187 million patients in the US do not take their medications as prescribed, primarily due to poor medication adherence. Identified barriers to medication nonadherence include:

- Fragmentation across the health care system, which can limit care coordination or make it difficult for physicians to easily access patient information across different care settings.
- The complexity of the drug therapies, which may lead to a patient’s perceived fear of side effects from the medication(s) or general confusion about the regimen.
- Poor communication between a provider and a patient about the medications, or difficulty explaining and understanding the benefits and adverse effects of complex drug therapies.
- Unintentional patient behavioral factors, such as forgetfulness.
- Patients’ physical or cognitive impairments.
- Socioeconomic factors, such as low health literacy, and high medication costs, as well as lack of transportation to fill their prescriptions at a pharmacy.
- Newly diagnosed, older heart failure patients with comorbid conditions, polypharmacy, and poor sleep.

Physicians can improve medication adherence by:

- Asking if the patient has been taking medications as prescribed.
- Developing a differential diagnosis of nonadherence.
- Tailor the solution to the problem (i.e. adherence solution for a nonadherence problem)
- Prescribe the right drug at the right dose
- Involving the entire care team with medication adherence
- Provide health coaching for patients with chronic conditions
- Develop collaborative care plans
- Integrating a behavioral health specialist into practice
- Use motivational interviewing to encourage patients to change unhealthy behaviors

Physicians can improve patient satisfaction with the referral process by using readily available strategies and tools such as, improving internal office communication, engaging patients in scheduling, facilitating the appointment, tracking referral results, analyzing data for improvement opportunities, and gathering patient feedback.

Physicians may improve the efficacy of prescribed cardiovascular medications by engaging in continuing medical education that provides practical integration of current evidence-based guideline-directed medical therapy into their standards of care, including, but not limited to the following the joint guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA).

The American Academy of Family Physicians Academy has participated in the Core Measures Collaborative (the Collaborative) convened by America’s Health Insurance Plans (AHIP) since
August 2014. The Collaborative is a multi-stakeholder effort working to define core measure sets of various specialties promoting alignment and harmonization of measure use and collection across both public and private payers.

Participants in the Collaborative included Centers for Medicare and Medicaid Services (CMS), the National Quality Forum (NQF), private payers, provider organizations, employers, and patient and consumer groups. This effort exists to decrease physician burden by reducing variability in measure selection, specifications and implementation—making quality measurement more useful and meaningful for consumers, employers, as well as public and private clinicians.

With significant AAFP input, a PCMH/ACO/Primary Care Core Measure Set has been developed for primary care. The goal of this set is to decrease burden and allow for more congruence between payer reporting programs.41

Resources: Evidence-Based Practice Recommendations/Guidelines/Performance Measures
- ACC/AHA Joint Guidelines20,40
- American College of Chest Physicians (ACCP) 2016 guidelines on antithrombotic therapy for venous thromboembolic (VTE) disease42
- NICE: Medicines adherence. Involving patients in decisions about prescribed medicines and supporting adherence43
- Coronary Artery Disease/Coronary Heart Disease. AFP Journal collection44
- Atrial Fibrillation. AFP Journal Collection45
- Heart Failure. AFP Journal Collection46
- Hypertension. AFP Journal Collection47
- Updated Guidelines on Outpatient Anticoagulation22
- Medication adherence: we didn't ask and they didn't tell29
- Health Coaching: Teaching Patients to Fish30
- An organized approach to chronic disease care48
- The integrated summary: a documentation tool to improve patient care.49
- Engaging Patients in Collaborative Care Plans31
- Encouraging patients to change unhealthy behaviors with motivational interviewing33
- Envisioning new roles for medical assistants: strategies from patient-centered medical homes34
- Health coaching for patients with chronic illness35
- Adding health education specialists to your practice36
- Improving anticoagulation management at the point of care37
- Simple tools to increase patient satisfaction with the referral process38
- FamilyDoctor.org. High Blood Pressure | Overview (patient education)50
- FamilyDoctor.org. Arrhythmia | Overview (patient education)51
- FamilyDoctor.org. Heart Failure | Overview (patient education)52
- FamilyDoctor.org. Deep Vein Thrombosis | Treatment (patient education)53
- FamilyDoctor.org. Caregiving: Caring for an Elderly Relative - Managing Medicines (patient education)54
2018 AAFP FMX Needs Assessment

- FamilyDoctor.org. Seniors: Managing Your Medications (patient education)
- FamilyDoctor.org. Working With Your Doctor (patient education)
- FamilyDoctor.org. Prescription Medicines (patient education)

References


23. CenterWatch. FDA Approved Drugs by Medical Condition. 2017;


41. American Academy of Family Physicians (AAFP). PCMH/ACO/Primary Care Core Measure Set. 2016;


44. American Academy of Family Physicians (AAFP). Coronary Artery Disease/Coronary Heart Disease. *AFP Journal Collection* 2014;


52. FamilyDoctor.org. Heart Failure | Overview. 2000;


